Key result
PVI-only cryoballoon ablation shows noninferior atrial arrhythmia recurrence in HFrEF versus non-HFrEF patients.
Why the study?
Prospective data evaluating a PVI-only strategy in HFrEF were lacking, and no studies had directly compared ablation efficacy between patients with and without HFrEF.
Does a PVI-only approach using cryoballoon ablation provide noninferior rhythm control in patients with atrial fibrillation and HFrEF compared to those without HFrEF?
Observational (n=1,420)
No
Does a PVI-only approach using cryoballoon ablation provide noninferior rhythm control in patients with atrial fibrillation and HFrEF compared to those without HFrEF?
A PVI-only cryoballoon ablation strategy for atrial fibrillation provides noninferior rhythm control and similar procedural safety in patients with HFrEF compared to those without HFrEF.
Answers are grounded in this paper and cite their sources.
Observational PVI data in HFrEF are hypothesis-generating; leaves open whether efficacy matches patients without HFrEF.
BACKGROUND: Atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) are both associated with increased morbidity and mortality. Ablation-based rhythm control, particularly using radiofrequency ablation with disparate strategies, has demonstrated clinical benefit. However, prospective data evaluating a pulmonary vein isolation (PVI)-only strategy in HFrEF are lacking, and no studies have directly compared ablation efficacy between patients with and without HFrEF. OBJECTIVES: This study sought to assess whether a PVI-only approach using cryoballoon ablation in patients with HFrEF (LVEF ≤40%) is noninferior to PVI-only in patients without HFrEF regarding rhythm control efficacy, and to describe safety outcomes. METHODS: We conducted a prospective, investigator-initiated, single-center, noninferiority, observational study with propensity score matching. The primary efficacy endpoint was the first documented recurrence of any atrial arrhythmia after a 90-day blanking period. Safety endpoints included death, cerebrovascular events, and procedure-related adverse events. RESULTS: A total of 1,420 patients (paroxysmal and persistent AF) underwent PVI. With propensity score matching, 1,044 patients were analyzed in a 1:5 ratio. Over a mean follow-up of 2 years, the primary efficacy endpoint occurred in 76 (43.7%) of 174 patients with HFrEF and in 379 (43.6%) of 870 without HFrEF (HR: 1.01; 95% CI: -∞ to 1.24; P = 0.005 for noninferiority). The incidence of all-cause mortality was numerically higher in patients with HFrEF (6.3% vs 3.4%; P = 0.07), while rates of procedure-related safety events were similar between groups (2.9% vs 4.1%; P = 0.53). CONCLUSIONS: In patients with AF undergoing ablation, a PVI-only approach shows noninferior rhythm control efficacy and comparable procedural safety in patients with HFrEF compared with those without HFrEF. (Cryoballoon Pulmonary Isolation for Atrial Fibrillation With Heart Failure [POLAR-HF]; NCT04461691).
No takes yet. Share an insight, caveat, or question.
Boehmer et al. (2025) conducted an observational in Atrial fibrillation and heart failure with reduced ejection fraction (n=1,420). PVI-only approach in HFrEF (LVEF ≤40%) vs. PVI-only approach without HFrEF was evaluated on First documented recurrence of any atrial arrhythmia after a 90-day blanking period (HR 1.01, 95% CI -∞ to 1.24, p=0.005 for noninferiority). A PVI-only approach using cryoballoon ablation in patients with HFrEF was noninferior to those without HFrEF for atrial arrhythmia recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: